Safety and Efficacy of Two Different Dose Regimens of IFX-1 as Add-On to Standard of Care in Subjects with GPA and MPA: IXPLORE

Study Findings: The study drug, vilobelimab, was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of care.

ClinicalTrials.gov ID: NCT03712345

Study Dates: 2018-2021

Disease(s): Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA)